Zymergen Inc.
0.0 %
0.0 %
Yet to be announced
Company Overview
Note: Zymergen Inc. (ZY) was acquired by Ginkgo Bioworks (DNA) in an all-stock transaction that closed in July 2022.
Zymergen was a biotechnology company that designed, engineered, and optimized microbes for industrial applications. The company used artificial intelligence, automation, and proprietary software to develop bio-based materials for various industries including electronics, consumer care, and agriculture.
Revenue Sources
PassBased on the company's financial reports and business model, Zymergen's revenue came from its biofacturing platform and research collaborations. These activities involve the engineering of microorganisms and development of bio-based materials, which are not inherently haram activities.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| June 30, 2022 | $2.63m | $118.21m | - | $9.38m | 0.00% | 7.93% |
| March 31, 2022 | $4.79m | $76.45m | - | $8.04m | 0.00% | 10.52% |
| Dec. 31, 2021 | $3.07m | $80.69m | - | $6.4m | 0.00% | 7.93% |
| Sept. 30, 2021 | $4.08m | $82.85m | $7,000 | $2.81m | 0.17% | 3.39% |
As the company was still in early development stage and not yet in its mature operational phase, with minimal revenue compared to expenses, we will skip the interest ratio checks. The company was primarily in R&D mode, developing its biofacturing platform and products.
Operational Ethics
PassBased on available information from SEC filings and company reports, there is no evidence of significant ongoing associations with entities involved in human rights violations such as the state of Israel or the Chinese Communist Party.
Comments